Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 214 matching trials from the live ClinicalTrials.gov search.
Conditions
Generalized Anxiety Disorder
Interventions
Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
36
States / cities
Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Duloxetine for Treatment of Painful Temporomandibular Joint Disorder

NCT00981149
Conditions
Temporomandibular Joint Disorders
Interventions
duloxetine, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Chronic Low-back Pain
Interventions
Algorithmically informed randomization (taking into account phenotypes), Physical Therapy (PT) and Exercise, Cognitive-Behavioral Therapy for Pain (PRISM-CBT), mHealth Acupressure Self-Management:, Duloxetine
Device · Behavioral · Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Diabetic Neuropathic Pain, Chronic Low Back Pain
Interventions
donepezil, duloxetine, donepezil 2.5 mg and duloxetine 30mg, placebo, gabapentin
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Cleveland, Ohio
Conditions
Major Depressive Disorder
Interventions
Placebo, Cariprazine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
819 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
39
States / cities
Garden Grove, California • National City, California • Oceanside, California + 34 more
Conditions
CIPN - Chemotherapy-Induced Peripheral Neuropathy, Pain
Interventions
Scrambler Therapy, Questionnaire and Physical Exam
Device · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Depression
Interventions
Escitalopram, Duloxetine, Cognitive behavioral therapy (CBT)
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Anxious Depression, Depression
Interventions
Escitalopram, Duloxetine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Major Depressive Disorder
Interventions
TC-5214, Duloxetine, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Beverly Hills, California • Chino, California • Garden Grove, California + 22 more
Conditions
Breast Cancer, Musculoskeletal Complications, Pain
Interventions
duloxetine hydrochloride, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years · Female only
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
714
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Jonesboro, Arkansas + 475 more
Completed Phase 2 Interventional Results available

Pilot Study of Duloxetine in Psychological Resilience

NCT00331799
Conditions
Major Depressive Disorder
Interventions
Duloxetine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 4 Interventional Results available

The Back Pain Consortium Research Program Study

NCT04870957
Conditions
Chronic Low-back Pain
Interventions
PainGuide, MBSR, PT and exercise, Self -administered acupressure, Duloxetine, Pro-Diary monitor
Behavioral · Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 70 Years
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Phase 4 Interventional Results available

Duloxetine Treatment in Elderly With Dysthymia

NCT01852383
Conditions
Depression, Dysthymic Disorder
Interventions
Duloxetine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Anxiety Disorders
Interventions
Duloxetine Hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
19
States / cities
Sherman Oaks, California • Fort Myers, Florida • Atlanta, Georgia + 16 more
Conditions
Major Depressive Disorder
Interventions
duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
7 Years to 17 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
22
States / cities
Dothan, Alabama • Chandler, Arizona • El Centro, California + 19 more
Conditions
Depression
Interventions
Standard antidepressant therapy (SADT), Motivational antidepressant therapy (MADT)
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 79 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Pain, Chronic
Interventions
Opioid, Opioid Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Major Depressive Disorder
Interventions
AZD2066, Placebo, Duloxetine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
13
States / cities
Garden Grove, California • San Diego, California • Jacksonville, Florida + 10 more
Conditions
Sphincter of Oddi Dysfunction
Interventions
Duloxetine
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Charleston, South Carolina
Completed Phase 4 Interventional Results available

Minimal Opioid Use After Total Hip Replacement (THR)

NCT03090152
Conditions
Osteoarthritis, Hip
Interventions
Periarticular injection (Deep injection), Periarticular injection (Superficial injection), Bupivacaine, Placebo
Procedure · Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Results available

Duloxetine Versus Pregabalin for Alcohol Dependence

NCT00929344
Conditions
Alcohol Dependence
Interventions
Pregabalin, Duloxetine, Standardized behavioral therapy, Placebo
Drug · Behavioral
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
La Jolla, California
Conditions
Depressive Disorder
Interventions
Duloxetine Hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Knee Osteoarthritis
Interventions
Duloxetine, Celecoxib, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
41 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Chronic Low-back Pain
Interventions
Enhanced Self-Care (ESC), Acceptance and Commitment Therapy (ACT), Evidence-Based Exercise and Manual Therapy (EBEM), Duloxetine
Behavioral · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
1,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Redwood City, California • San Diego, California • San Francisco, California + 9 more